CN105658647B - 化合物的盐 - Google Patents

化合物的盐 Download PDF

Info

Publication number
CN105658647B
CN105658647B CN201480057947.4A CN201480057947A CN105658647B CN 105658647 B CN105658647 B CN 105658647B CN 201480057947 A CN201480057947 A CN 201480057947A CN 105658647 B CN105658647 B CN 105658647B
Authority
CN
China
Prior art keywords
salt
dihydro
base
methyl
dioxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480057947.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN105658647A (zh
Inventor
B·奥利尼克
B·凯尔
M-H·欣茨
C·菲尔斯特纳
M·杰斯科
J·埃克斯达夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CN105658647A publication Critical patent/CN105658647A/zh
Application granted granted Critical
Publication of CN105658647B publication Critical patent/CN105658647B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201480057947.4A 2013-11-08 2014-11-05 化合物的盐 Active CN105658647B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13192177.7 2013-11-08
EP13192177 2013-11-08
PCT/EP2014/073801 WO2015067652A1 (de) 2013-11-08 2014-11-05 Salze von 1 -(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1 r)-4-(trifluormethyl)-2,3-dihydro-1h-inden-1 -yl]-1,2,3,4-tetrahydropyrimidin-5-carbonsäure

Publications (2)

Publication Number Publication Date
CN105658647A CN105658647A (zh) 2016-06-08
CN105658647B true CN105658647B (zh) 2019-09-06

Family

ID=49552231

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480057947.4A Active CN105658647B (zh) 2013-11-08 2014-11-05 化合物的盐

Country Status (32)

Country Link
US (1) US9926305B2 (cg-RX-API-DMAC7.html)
EP (1) EP3066097B1 (cg-RX-API-DMAC7.html)
JP (1) JP6446051B2 (cg-RX-API-DMAC7.html)
KR (1) KR102351418B1 (cg-RX-API-DMAC7.html)
CN (1) CN105658647B (cg-RX-API-DMAC7.html)
AP (1) AP2016009181A0 (cg-RX-API-DMAC7.html)
AU (1) AU2014345599B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016010253A8 (cg-RX-API-DMAC7.html)
CA (1) CA2929780C (cg-RX-API-DMAC7.html)
CL (1) CL2016001096A1 (cg-RX-API-DMAC7.html)
CY (1) CY1119520T1 (cg-RX-API-DMAC7.html)
DK (1) DK3066097T3 (cg-RX-API-DMAC7.html)
EA (1) EA033132B1 (cg-RX-API-DMAC7.html)
ES (1) ES2645480T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20171603T1 (cg-RX-API-DMAC7.html)
HU (1) HUE035021T2 (cg-RX-API-DMAC7.html)
IL (1) IL245407B (cg-RX-API-DMAC7.html)
LT (1) LT3066097T (cg-RX-API-DMAC7.html)
MA (1) MA39020A1 (cg-RX-API-DMAC7.html)
ME (1) ME02907B (cg-RX-API-DMAC7.html)
MX (1) MX366848B (cg-RX-API-DMAC7.html)
MY (1) MY190108A (cg-RX-API-DMAC7.html)
NO (1) NO3066097T3 (cg-RX-API-DMAC7.html)
PH (1) PH12016500853B1 (cg-RX-API-DMAC7.html)
PL (1) PL3066097T3 (cg-RX-API-DMAC7.html)
PT (1) PT3066097T (cg-RX-API-DMAC7.html)
RS (1) RS56509B1 (cg-RX-API-DMAC7.html)
SA (1) SA516371082B1 (cg-RX-API-DMAC7.html)
SI (1) SI3066097T1 (cg-RX-API-DMAC7.html)
TN (1) TN2016000170A1 (cg-RX-API-DMAC7.html)
UA (1) UA117686C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015067652A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3338780A1 (de) 2016-12-20 2018-06-27 Bayer Pharma Aktiengesellschaft Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind
CA3061444A1 (en) * 2017-04-27 2018-11-01 Bayer Aktiengesellschaft Selective adrenoreceptor .alpha.2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad)
WO2022135502A1 (zh) * 2020-12-25 2022-06-30 广东东阳光药业有限公司 多取代的尿嘧啶衍生物及其用途
KR20240170943A (ko) * 2022-04-05 2024-12-05 스코프라 시앙스 쌍테 에 휴마이네스 에스.에.쎄. 혈전성 또는 혈전색전성 장애에서 혈전의 선택적인 해소에 사용하기 위한 키마제의 억제제

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013167495A1 (de) * 2012-05-09 2013-11-14 Bayer Pharma Aktiengesellschaft Bicyclisch-substituierte uracile und ihre verwendung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032881A1 (en) * 2000-10-19 2002-04-25 Nippon Kayaku Kabushiki Kaisha Novel remedies or preventives for angiostenosis
AT511788A1 (de) 2011-07-29 2013-02-15 Georg Dr Gaul Vorrichtung zur vorgebbaren anordnung eines stents
EP2822405A4 (en) * 2012-03-05 2015-04-29 Gratuk Technologies Pty Ltd FOOD SUPPLEMENTS
CA2929763A1 (en) * 2013-11-08 2015-05-14 Bayer Pharma Aktiengesellschaft Substituted uracils as chymase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013167495A1 (de) * 2012-05-09 2013-11-14 Bayer Pharma Aktiengesellschaft Bicyclisch-substituierte uracile und ihre verwendung

Also Published As

Publication number Publication date
PH12016500853B1 (en) 2021-03-24
CA2929780A1 (en) 2015-05-14
EA033132B1 (ru) 2019-08-30
US20160289220A1 (en) 2016-10-06
US9926305B2 (en) 2018-03-27
EP3066097B1 (de) 2017-08-16
AU2014345599A1 (en) 2016-05-19
HUE035021T2 (en) 2018-03-28
HRP20171603T1 (hr) 2017-12-01
HK1222171A1 (zh) 2017-06-23
NZ719532A (en) 2021-06-25
SI3066097T1 (sl) 2017-12-29
CY1119520T1 (el) 2018-03-07
LT3066097T (lt) 2018-02-12
UA117686C2 (uk) 2018-09-10
JP6446051B2 (ja) 2018-12-26
MA39020A1 (fr) 2017-04-28
CL2016001096A1 (es) 2016-12-23
PL3066097T3 (pl) 2018-01-31
KR20160078980A (ko) 2016-07-05
RS56509B1 (sr) 2018-02-28
CA2929780C (en) 2022-03-22
NO3066097T3 (cg-RX-API-DMAC7.html) 2018-01-13
BR112016010253A2 (pt) 2017-08-08
DK3066097T3 (da) 2017-11-06
CN105658647A (zh) 2016-06-08
TN2016000170A1 (en) 2017-10-06
PT3066097T (pt) 2017-11-10
PH12016500853A1 (en) 2016-06-20
KR102351418B1 (ko) 2022-01-17
JP2016535096A (ja) 2016-11-10
MX366848B (es) 2019-07-26
WO2015067652A1 (de) 2015-05-14
IL245407B (en) 2019-10-31
SA516371082B1 (ar) 2019-05-16
MX2016005971A (es) 2016-08-11
ES2645480T3 (es) 2017-12-05
AU2014345599B2 (en) 2019-02-14
BR112016010253A8 (pt) 2021-06-22
EP3066097A1 (de) 2016-09-14
ME02907B (me) 2018-04-20
AP2016009181A0 (en) 2016-04-30
MY190108A (en) 2022-03-29
EA201600381A1 (ru) 2016-10-31
IL245407A0 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
TWI304062B (en) N-(pyridin-2-yl)-sulfonamide derivatives
CN105658647B (zh) 化合物的盐
EA031222B1 (ru) Бициклически замещённые урацилы и их применение
JP2019524710A5 (cg-RX-API-DMAC7.html)
US20160244415A1 (en) Substituted uracils as chymase inhibitors
WO2017173999A1 (zh) 抗乙肝病毒的吡唑-噁唑烷酮类化合物
TWI861165B (zh) 新穎嗒
CN101506174B (zh) 基于哒嗪酮骨架的半胱天冬蛋白酶抑制剂
HK1222171B (zh) 化合物的盐
CN116003386B (zh) 一种氘代n-苄基吡啶酮吡唑甲酰胺类化合物、药物组合物和用途
NZ719532B2 (en) Salts of 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)- 4-(trifluormethyl)-2,3-dihydro-1h-inden-1-yl]-1,2,3,4-tetrahydropyrimidin-5-carboxylic acid
CN106496106B (zh) 丙氨酸衍生物
CN111793066B (zh) 苯并五元杂环磺酰胺类化合物、其制备方法、药物组合物及应用
JPH03232885A (ja) キナゾリン誘導体およびその塩
CN121135736A (zh) 吡喃并吡啶类化合物、其制备方法、药物组合物及应用
CN120774918A (zh) 蛋白降解剂类化合物及其制备方法、药物组合物和应用
WO2021036495A1 (zh) 新型苯乙酸衍生物、其制备方法及其作为药物的用途
CN113004283A (zh) 作为血浆激肽释放酶抑制剂的四环类化合物及其用途
HK1223925B (zh) 醛糖还原酶抑制剂及其用途
JP2012512204A (ja) ４−（｛（４−カルボキシブチル）［２−（２−｛［４−（２−フェニルエチル）ベンジル］オキシ｝フェニル）エチル］アミノ｝メチル）安息香酸の変態ｉ

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1222171

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant